The institutional buying is modest in scale relative to the $3.2B market cap and is not corroborated by insider buying (confluence score 11/100, divergent). Monitor the upcoming FDA decision on darovasertib and the next 10-Q for cash burn and pipeline updates.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $31.33entry
- T+1 · 13d ago +3.29%α +1.64% · $32.36
- T+5 · 7d ago +1.34%α +1.93% · $31.75
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Four institutional asset managers added to their IDYA positions in Q3 2026, collectively increasing holdings by $3.3M to a total of $12.4M. The buying follows the company's NDA submission for darovasertib in metastatic uveal melanoma and the closure of the Phase 3 OptimUM-010 trial, which is expected to save $100-125M for reallocation to other pipeline programs. No institutional selling was reported in the cluster.
Key Financial Metrics
Institutional Positions
Net institutional flow: $3.3M
▲ Buyers (4)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Mirae Asset Global Investments Co. | ADD | +25.5% | $189.0K | $43.0K |
| Strs Ohio | ADD | +26.3% | $1.6M | $381.0K |
| Alps Advisors | ADD | +44% | $4.9M | $1.6M |
| Congress Asset Management | ADD | +25.5% | $5.7M | $1.3M |
Key Facts
- 4 institutional buyers added $3.3M in aggregate, with total holdings of $12.4M
- No institutional sellers in the cluster
- NDA submission for darovasertib in metastatic uveal melanoma completed
- Phase 3 OptimUM-010 trial closed, expected to save $100-125M
- Cash at $1.15B with runway into 2030 unchanged
- Confluence score 11/100 (divergent), no open-market insider buying
Financial Impact
4 institutions added $3.3M in net new positions, totaling $12.4M in current holdings
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- No insider buying to corroborate institutional conviction
- All buyers are asset managers, not specialist biotech funds, signal is moderate
- Regulatory risk on darovasertib NDA outcome
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-IDYA-2026-Q3 |
Track record
13 reports on IDYA
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Viewing Entry $31.33 to $31.75 ▲ +1.34% +1.93% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 ▲ +1.34% +1.93% vs SPY
- Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 ▲ +6.62% +5.64% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 ▲ +2.02% +2.12% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 ▼ −0.30% −2.01% vs SPY
- Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 ▼ −8.39% −7.96% vs SPY
- Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 ▼ −10.76% −7.33% vs SPY
- Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 ▼ −7.70% −5.28% vs SPY
- Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 ▼ −2.82% +1.00% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 ▼ −2.16% −3.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers